HK Stock Market Move | HBM Holdings-B (02142) increased by over 5%, with its stock price doubling in the past year. The company is facing various positive developments.

HBM HOLDINGS-B (02142) rose by over 5%, with the stock price more than doubling within the year. As of the time of writing, it rose by 5.11%, reaching 5.76 Hong Kong dollars, with a trading volume of 52.07 million Hong Kong dollars. On the news front, HepBo Pharmaceuticals and Enginius recently announced a strategic partnership. According to the agreement, the two parties will combine HepBo's leading technology platform, proprietary data sets, and rich experience in antibody development with Enginius's technical advantages in building an integrated AI-driven drug R&D platform to jointly promote AI-enabled antibody discovery algorithms and application development. In addition, they will also collaborate on early drug discovery projects for novel specific antibodies, aiming to provide innovative solutions for unmet medical needs in the fields of immunology, oncology, and neuroscience. Previously, the company announced a profit joy, expecting a surplus of between 7.3 million and 22 million RMB for the fiscal year ending on December 31, 2024. During the period, the company achieved a historical high cash surplus of 220 million RMB. The sustainable profit-making capability is mainly attributed to maintaining strategic partnerships with global pharmaceutical companies and leading biotechnology companies continuously through its unique business model accelerating growth; the recurring part of the revenue continued to grow in 2024, including platform-based research revenue and milestone payments received from partners as cooperation projects mature.